Incyte Names New Member to Its Board of Directors
Incyte Corporation (Nasdaq:INCY) today announced the appointment of Jacqualyn “Jackie” A. Fouse, Ph.D., as a new member of the
Board of Directors, effective November 14, 2017.
“We are pleased to welcome Jackie to Incyte. Her impressive background will further strengthen and add to the experience of our
Board and leadership team,” stated Hervé Hoppenot, Incyte’s Chairman and Chief Executive Officer. “We look forward to benefiting
from her counsel as we continue to build Incyte into a global biopharmaceutical company.”
“I am excited to join Incyte at such an important time in its evolution. The Company’s commitment to scientific excellence has
positively impacted the lives of thousands of patients treated with Jakafi, and simultaneously produced a development pipeline of
product candidates that is much-admired in the biopharma space,” stated Dr. Fouse. “I look forward to working closely with the rest
of the team to advance Incyte and its science as we aim to continue helping patients in need.”
Dr. Fouse is currently the Executive Chair of Dermavant Sciences, a position she has held since July 2017. Prior to joining
Dermavant, Dr. Fouse served in various senior capacities at Celgene Corporation, most recently as Strategic Advisor to the
Management Executive Committee. Her previous roles at Celgene included President and Chief Operating Officer; President, Hematology
and Oncology; and Chief Financial Officer. Prior to joining Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited,
and was previously Chief Financial Officer and Head of Corporate Strategy at Alcon Laboratories, Inc. Dr. Fouse currently serves as
a Director of Dick’s Sporting Goods, Inc.
Dr. Fouse earned her B.A. and M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including without
limitation statements regarding the Company’s efforts to continue to grow as a global biopharmaceutical company, contain
predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current
expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks related to
market competition, the results of and risks associated with research and development, risks and uncertainties associated with
sales, marketing and distribution requirements, and other risks detailed from time to time in the Company’s reports filed with the
Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2017. Incyte disclaims any intent or
obligation to update these forward-looking statements.
Incyte Corporation
Media
Catalina Loveman, +1 302-498-6171
cloveman@incyte.com
Investors
Michael Booth, DPhil, +1 302-498-5914
mbooth@incyte.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171030006206/en/